KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Charles River Laboratories International (CRL) Debt to Equity: 2009-2025

Historic Debt to Equity for Charles River Laboratories International (CRL) over the last 17 years, with Sep 2025 value amounting to $0.64.

  • Charles River Laboratories International's Debt to Equity rose 4.31% to $0.64 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.64, marking a year-over-year increase of 4.31%. This contributed to the annual value of $0.65 for FY2024, which is 12.07% down from last year.
  • Charles River Laboratories International's Debt to Equity amounted to $0.64 in Q3 2025, which was down 7.69% from $0.69 recorded in Q2 2025.
  • Charles River Laboratories International's 5-year Debt to Equity high stood at $1.19 for Q3 2021, and its period low was $0.61 during Q3 2024.
  • Over the past 3 years, Charles River Laboratories International's median Debt to Equity value was $0.73 (recorded in 2024), while the average stood at $0.72.
  • Per our database at Business Quant, Charles River Laboratories International's Debt to Equity grew by 12.36% in 2021 and then plummeted by 31.98% in 2023.
  • Charles River Laboratories International's Debt to Equity (Quarterly) stood at $1.05 in 2021, then decreased by 13.51% to $0.91 in 2022, then decreased by 19.09% to $0.73 in 2023, then decreased by 12.07% to $0.65 in 2024, then grew by 4.31% to $0.64 in 2025.
  • Its last three reported values are $0.64 in Q3 2025, $0.69 for Q2 2025, and $0.78 during Q1 2025.